Tenofovir (GS 1278) Disoproxil Fumarate

Catalog No.S1400 Synonyms: Tenofovir DF

For research use only.

Tenofovir Disoproxil Fumarate (GS-1278, Tenofovir DF) belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.

Tenofovir (GS 1278) Disoproxil Fumarate Chemical Structure

CAS No. 202138-50-9

Selleck's Tenofovir (GS 1278) Disoproxil Fumarate has been cited by 19 publications

Purity & Quality Control

Choose Selective Reverse Transcriptase Inhibitors

Other Reverse Transcriptase Products

Biological Activity

Description Tenofovir Disoproxil Fumarate (GS-1278, Tenofovir DF) belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.
Targets
HIV reverse transcriptase [1]
(Cell-free assay)
In vitro

Tenofovir is eliminated from systemic circulation renally through a combination of glomerular filtration and active tubular secretion. Tenofovir is not a substrate for human organic cation transporter type 1 (hOCT1) or hOCT2. Tenofovir accumulates to fivefold lower levels in MRP4-overexpressing cells, and its accumulation could be increased by an MRP inhibitor. [1] Tenofovir produces no significant changes in mitochondrial DNA (mtDNA) levels in human hepatoblastoma (HepG2) cells, skeletal muscle cells (SkMCs), or renal proximal tubule epithelial cells. Tenofovir elevates lactate production by less than 20% in HepG2 cells or SkMCs. [2] Tenofovir is efficiently phosphorylated to tenofovir diphosphate (TFV-DP) in both HepG2 cells and primary human hepatocytes. Tenofovir has a 50% effective concentration of 1.1 mM against HBV in cell-based assays, and potency is improved > 50-fold by the addition of bis-isoproxil progroups. Tenofovir has previously demonstrated full activity against lamivudine-resistant HBV in vitro and clinically. [3] Tenofovir inhibits the proliferation of liver-derived HepG2 cells and normal skeletal muscle cells with CC(50) values of 398 μM and 870 μM, respectively. Tenofovir shows substantially weaker effects on proliferation and viability of renal proximal tubule epithelial cells than cidofovir, a related nucleotide analog with the potential to induce renal tubular dysfunction. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MT2 MWrGeY5kfGmxbjDhd5NigQ>? MnLEOUBl[Xm| MW\Jcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgbY4hf2muZDD0fZBmKEiLVjCzZUBqdm[nY4Tl[EBOXDJiY3XscJMh[W[2ZYKgOUBl[Xm|LDDFR|UxRTBwMEG1{txO NULreYR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OlI{PjZpPkG3OVYzOzZ4PD;hQi=>
HepG2 NXm5[3dtS3m2b4TvfIlkcXS7IHHzd4F6 MVy5JIRigXN? NFG0UnNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA6KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIvOzIQvF2= M{fDXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OEi4OlYzLz5zN{i4PFY3OjxxYU6=
HepG2 M{XzfWFvfGm4aYLhcEBie3OjeR?= M33XXFkh\GG7cx?= MlqyRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGIhfmm{dYOgbY5n\WO2ZXSgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiOTDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD13LkJOwG0> NV3DZ4M4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4PFg3PjJpPkG3PFg5PjZ{PD;hQi=>
MT-2 MXLBcpRqfmm{YXygZZN{[Xl? Mn35RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDNWE0zKGOnbHzzJIJ6KHS5bzDmc4xlKGSrbIX0bY9vKG2ndHjv[EBqdiCycnXz[Y5k\SCxZjCxNEUhTkKVLDDFR|UxRTBwMEC2PO69VQ>? NU\pcZdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNFQxOTBpPkG5NVA1ODFyPD;hQi=>
MT2 MWXBcpRqfmm{YXygZZN{[Xl? NXfIW4RVSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDpcoZm[3SnZDDpckBpfW2jbjDNWFIh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjygTWM2OD1yLkW0{txO MmPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3OU[4PFUoRjF7NUm2PFg2RC:jPh?=
HeLa P4/R5 MlXHRY51cX[rcnHsJIF{e2G7 NH\QflFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEhWDRxUkWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdixiSVO1NF01NjgQvF2= MlvGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3OU[4PFUoRjF7NUm2PFg2RC:jPh?=
HeLa P4/R5 MVXBcpRqfmm{YXygZZN{[Xl? NWr5SVFiSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDoZZJjd3KrbnegdoV3\XK|ZTD0doFve2O{aYD0ZZNmKEt4NWKgcZV1[W62IHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEhWDRxUkWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdixiSVO1NF0yOS52zszN M2TGcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUm2PFg2Lz5zOUW5Olg5PTxxYU6=
human bone marrow cells NFG3dlBEgXSxdH;4bYNqfHliYYPzZZk> Mlu4NlQhcHK| NVG4VXZkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[m:wZTDtZZJzd3diY3XscJMh[W[2ZYKgNlQhcHK|IHL5JGJHXS2HIHHzd4F6NCCFQ{WwQVAvQc7:TR?= NI\iV2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzPVYxQSd-MkC0N|k3ODl:L3G+
human bone marrow cells MlzER5l1d3SxeHnjbZR6KGG|c3H5 NHH5XlkzPCCqcoO= M3vPb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJwdmVibXHydo94KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDHUU1ETlViYYPzZZktKEOFNUC9NU46|ryP MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR|OU[wPUc,OjB2M{m2NFk9N2F-
HeLa-T4 MYDBcpRqfmm{YXygZZN{[Xl? MYK0PEBpenN? MVjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDzbY5odGVvcn;1coQhUEmYMTDOUHgvVHW6LWKgbIFz[m:{aX7nJIlv[WO2aY\heIlv\yCvdYTheIlwdnNiaX6g[Y53NCC4cIKgZY5lKGOjcoLp[ZMh\mm{ZX\sfUBtfWOrZnXyZZNmKGenbnWgbY4heGyjY3Wgc4YhdmWoIHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEuXDRiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB2ODDodpMh[nliZYjv[4Vvd3W|IGLUJIF{e2G7LDDFR|UxRTBwMECyPe69VQ>? MoLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyNkCxNFgoRjJzME[wNVA5RC:jPh?=
HeLa-T4 M2W1fGFvfGm4aYLhcEBie3OjeR?= NYXPdnB1PDhiaILz MVzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDzbY5odGVvcn;1coQhUEmYMTDOUHgvVHW6LWKgbIFz[m:{aX7nJIlv[WO2aY\heIlv\yCvdYTheIlwdnNiaX6g[Y53NCC4cIKgZY5lKGOjcoLp[ZMh\mm{ZX\sfUBtfWOrZnXyZZNmKGenbnWgbY4heGyjY3Wgc4YhdmWoIHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEuXDRiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB2ODDodpMh[nliZYjv[4Vvd3W|IGLUJIF{e2G7LDDFR|k2RTBwMEO3{txO NVzjS4ZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOlAyODhpPkKxNFYxOTB6PD;hQi=>
HeLaT4 NYXPV2o1SW62aY\pdoFtKGG|c3H5 NHrWVJUzPCCqcoO= MlrjRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4lv\2ynLYLveY5lKEiLVkGgUmxZNky3eD3SJIhiemKxcnnu[{BqdmGldHn2ZZRqdmdibYX0ZZRqd26|IHnuJIVvfixidoDyJIFv\CClYYLybYV{KG[rcnXmcJkhdHWlaX\ldoF{\SCpZX7lJIlvKHCuYXPlJI9nKG6nZjDhd5Nme3OnZDDhd{Bt\X[nbDDv[kBqdm[nY4Tpc44hfXOrbnegbJVu[W5iSHXMZXQ1KGOnbHzzJJBz\XS{ZXH0[YQh\m:{IEK0JIhzeyCob3zsc5dm\CCkeTDlfJBwe2WmIITvJJZqNCCHQ{WwQVAvOTMQvF2= NW\rUGJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOlAyODhpPkKxNFYxOTB6PD;hQi=>
HeLaT4 Mk\BRY51cX[rcnHsJIF{e2G7 Mk\MRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4lv\2ynLYLveY5lKEiLVkGgUmxZNky3eD3SJIhiemKxcnnu[{BqdmGldHn2ZZRqdmdibYX0ZZRqd26|IHnuJIVvfixidoDyJIFv\CClYYLybYV{KG[rcnXmcJkhdHWlaX\ldoF{\SCpZX7lJIlvKHCuYXPlJI9nKG6nZjDhd5Nme3OnZDDhd{Bt\X[nbDDv[kAzKG2rboOgcYFodmW2aXOgcoFvd3CjcoTpZYx{NW2nZHH0[YQhcW6oZXP0bY9vKGmwIHj1cYFvKEinTHHUOEBk\WyuczD0doVifGWmIH\vdkAyNCCHQ{m5MlY:OC57Nd88US=> M376eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzME[wNVA5Lz5{MUC2NFExQDxxYU6=
HeLaT4 MXrDfZRwfG:6aXPpeJkh[XO|YYm= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiXDRiY3XscJMh[nliV2PUMVEh[XO|YYmsJGNEPTB;M{VOwG0> NYnVc49vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOlAyODhpPkKxNFYxOTB6PD;hQi=>
HeLaT4 Ml:1SpVv[3Srb36gZZN{[Xl? MnK1NlQhcHK| MlLSSJJ2\yC3cIThb4UhcW5iaIXtZY4hUGWOYWS0JINmdGy|IHHzd4V{e2WmIHHzJINwdXCxdX7kJJBmenOrc4SgcYVie3W{ZXSgZYZ1\XJiMzD0bY1meyC5YYPoc5V1KGG2IEGwNEB1cW2nIFXDPVUh\m:{IFjJWlEh\m:{IEK0JIhzew>? NYXKcm1iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOlAyODhpPkKxNFYxOTB6PD;hQi=>
HeLaT4 MlLiRY51cX[rcnHsJIF{e2G7 M3nablI1KGi{cx?= MkTyRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4lv\2ynLYLveY5lKEiLVkGgUmxZNky3eD3SJIhiemKxcnnu[{BqdmGldHn2ZZRqdmdibYX0ZZRqd26|IHnuJIVvfixidoDyJIFv\CClYYLybYV{KG[rcnXmcJkhdHWlaX\ldoF{\SCpZX7lJIlvKHCuYXPlJI9nKG6nZjDhd5Nme3OnZDDhd{Bt\X[nbDDv[kBqdm[nY4Tpc44hfXOrbnegbJVu[W5iSHXMZXQ1KGOnbHzzJJBz\XS{ZXH0[YQh[XRiMUCwJJRqdWViRVO5OUBnd3JiMkSgbJJ{KG[xbHzve4Vl MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB4MEGwPEc,OjFyNkCxNFg9N2F-
PBMC MX\BcpRqfmm{YXygZZN{[Xl? Mn7iO{Bl[Xm| MnPFRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCrbn\lZ5Rm\CCrbjDoeY1idiCSQl3DJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZpkhdWWjc4XybY5oKHKndnXyd4UhfHKjboPjdolxfGG|ZTDhZ5Rqfmm2eTDpckBk\WyuIIP1dIVzdmG2YX70JJBz\WmwY4XiZZRm\CC5aYToJINmdGy|IH\vcIxwf2WmIHL5JJZqemGuIHnu[oVkfGmxbjDt[YF{fXKnZDDh[pRmeiB5IHThfZMh[nlicnHkbY9i[3SrdnWgbY5kNCCHQ{WwQVAvODB2Nt88US=> NEKzcYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SwOVc6PCd-Mke0NFU4QTR:L3G+
HepG2.2.15 NITLfpFCdnSrdnnyZYwh[XO|YYm= MXyzJIRigXN? Mm\ZRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGJXKGmwZnXjeIVlKGmwIHj1cYFvKEincFeyMlIvOTViY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDEUmEhcW5iY3XscEB{fXCncn7heIFvfCCrbnP1ZoF1\WRiZn;yJFMh\GG7czDpckBxemW|ZX7j[UBw\iBzMDWgSmJUKG[xbHzve4VlKGK7IHPvcZBwfW6mIITy[YF1dWWwdDDpckBi[nOnbnPlJI9nKDFyJTDGRnMh\m:{IEOg[IF6eyCkeTDxVnQuWEOUIH3leIhw\CxiRVO1NF0xNjN2zszN Mor4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2MEW3PVQoRjJ5NEC1O|k1RC:jPh?=
HepG2.2.15 MX7DfZRwfG:6aXPpeJkh[XO|YYm= MoHwOkBl[Xm| Mly5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJwMj6xOUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOkBl[Xm|IHL5JHhVXCCjc4PhfUwhS0N3ME2yPU4z|ryP MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzRyNUe5OEc,Ojd2MEW3PVQ9N2F-
PBMC MoXWRY51cX[rcnHsJIF{e2G7 NWfiNZNnOzBibXnudy=> MXzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDDXGNTPC22cn;wbYMhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iUFjBMZN1cW23bHH0[YQhWEKPQzDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIHL5JI1m[XO3cnnu[{Bz\WS3Y4Tpc44hcW5icEK0JIFvfGmpZX6gdJJw\HWldHnvckBxemWrbnP1ZoF1\WRid3n0bEBk\WyuczDmc5IhOzBibXnud{Bnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQtKEmFNUC9NE4xQM7:TR?= NIjjdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4NlA3Pyd-Mki2PFIxPjd:L3G+
PBMC M4DUc2FvfGm4aYLhcEBie3OjeR?= MWWzNEBucW6| MXHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDDR3I2KHS{b4DpZ{BJUVZzIFLhUEBqdm[nY4Tl[EBqdiCqdX3hckBRUEFvc4TpcZVt[XSnZDDQRm1EKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBxOjRiYX70bYdmdiCycn;keYN1cW:wIIDy[Ylv[3WkYYTl[EB4cXSqIHPlcIx{KG[xcjCzNEBucW6|IH\vcIxwf2WmIHL5JJZqemGuIHnu[oVkfGmxbjDt[YF{fXKnZDDvckAtKEmFNUC9NE4zOs7:TR?= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6MkC2O{c,Ojh4OEKwOlc9N2F-
MT4 MVXBcpRqfmm{YXygZZN{[Xl? MWS2JIRigXN? M{LBW2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGNZS1J2LYTyc5Bq[yCKSW[tNUBPVDRvMzDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGGodHXyJFYh\GG7czDifUBZXFRiZInlJIJie2WmIHHzd4F6NCCHQ{WwQVQvQDoQvF2= Ml[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEKwOlcoRjJ6NkiyNFY4RC:jPh?=
MT4 MnTMRY51cX[rcnHsJIF{e2G7 M3j6eFYh\GG7cx?= M3j3[GFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJRmdm:ob4\pdk1z\XOrc4ThcpQhS1iFUkSteJJweGmlIFjJWk0yKE6OND2zJIhiemKxcnnu[{Bz\X[ncoPlJJRz[W6|Y4LpdJRie2ViS{[1VkBufXSjboSgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIFnfGW{IE[g[IF6eyCkeTDYWHQh\CxiRVO1NF0yOS5|zszN M4T6[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkiyNFY4Lz5{OE[4NlA3PzxxYU6=
HepG2.2.15 NH74SVlCdnSrdnnyZYwh[XO|YYm= MYHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIRnYhcW6oZXP0[YQhcW5iaIXtZY4hUGWyR{KuNk4yPSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ5l1d3CuYYPtbYMhTE6DIIP5cpRp\XOrczDifUBz\WWmIHHu[EBufW6laDDt[ZRpd2RuIFnDOVA:OC56Nd88US=> NWr4Umh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyNlM1PjBpPkOxNlI{PDZyPD;hQi=>
HepG2.2.15 M2rIPGN6fG:2b4jpZ4l1gSCjc4PhfS=> NEj5ToFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMj6yMlE2KGOnbHzzJIlv\mWldHXkJJdqfGhiSFLWMEBESzVyPUKwMlcy|ryP MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTJ{M{S2NEc,OzF{MkO0OlA9N2F-

Protocol (from reference)

Cell Research:

[5]

  • Cell lines: VK2 cells
  • Concentrations: 450 μM or 1,350 μM
  • Incubation Time: 15 min to 12 h
  • Method:

    VK2 cells were exposed to TDF (90 μM or 450 μM) and TFV (450 μM or 1,350 μM) in serum-free RPMI 1640 at 37°C for 15 min to 12 h. At different times postexposure, cells were washed with ice-cold PBS and metabolites were extracted overnight in 70% (vol/vol) methanol, followed by centrifugation at 18,000 × g for 10 min at 4°C. 

  • (Only for Reference)
Animal Research:

[6]

  • Animal Models: BALB/c mice
  • Dosages: 50, 500, or 1000 mg/kg
  • Administration: oral administration
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(157.35 mM)
Water Insoluble
Ethanol ''''44 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 635.51
Formula

C19H30N5O10P.C4H4O4

CAS No. 202138-50-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C.C(=CC(=O)O)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03576066 Completed Drug: ABI-H0731|Drug: SOC NUC|Drug: Placebo Oral Tablet Chronic Hepatitis B Assembly Biosciences June 11 2018 Phase 2
NCT03361956 Completed Drug: JNJ-56136379|Drug: Placebo|Drug: NA (ETV or TDF) Hepatitis B Janssen Sciences Ireland UC February 13 2018 Phase 2
NCT02985996 Completed Drug: Truvada|Drug: Genvoya HIV Infections Emory University|Centers for Disease Control and Prevention February 6 2017 Phase 1
NCT03043326 Recruiting Drug: Tenofovir Disoproxil Fumarate and Emtricitabine HIV Prevention Asociación Civil Impacta Salud y Educación Peru|Gilead Sciences January 23 2017 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tenofovir (GS 1278) Disoproxil Fumarate | Tenofovir (GS 1278) Disoproxil Fumarate supplier | purchase Tenofovir (GS 1278) Disoproxil Fumarate | Tenofovir (GS 1278) Disoproxil Fumarate cost | Tenofovir (GS 1278) Disoproxil Fumarate manufacturer | order Tenofovir (GS 1278) Disoproxil Fumarate | Tenofovir (GS 1278) Disoproxil Fumarate distributor